Trinity biotech announces positive pre-pivotal trial results for its next-generation continuous glucose monitor technology

Dublin, oct. 07, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in europe for its next-generation continuous glucose monitor (cgm) technology. the study assessed the analytical performance of cgm technology enhancements implemented by trinity biotech since acquiring the technology from waveform technologies in january 2024.
TRIB Ratings Summary
TRIB Quant Ranking